<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPR</journal-id>
<journal-id journal-id-type="hwp">spcpr</journal-id>
<journal-title>European Journal of Preventive Cardiology</journal-title>
<issn pub-type="ppub">2047-4873</issn>
<issn pub-type="epub">2047-4881</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1741826710394305</article-id>
<article-id pub-id-type="publisher-id">10.1177_1741826710394305</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Obesity</subject>
<subj-group subj-group-type="heading">
<subject>Original scientific paper</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Relation between body mass index, waist circumference, and cardiovascular outcomes in 19,579 diabetic patients with established vascular disease: the REACH Registry</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Dallongeville</surname><given-names>Jean</given-names></name>
<xref ref-type="aff" rid="aff1-1741826710394305">1</xref>
<xref ref-type="corresp" rid="corresp1-1741826710394305"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Bhatt</surname><given-names>Deepak L</given-names></name>
<xref ref-type="aff" rid="aff2-1741826710394305">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Steg</surname><given-names>Ph Gabriel</given-names></name>
<xref ref-type="aff" rid="aff3-1741826710394305">3</xref>
<xref ref-type="aff" rid="aff4-1741826710394305">4</xref>
<xref ref-type="aff" rid="aff5-1741826710394305">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ravaud</surname><given-names>Philippe</given-names></name>
<xref ref-type="aff" rid="aff6-1741826710394305">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wilson</surname><given-names>Peter W</given-names></name>
<xref ref-type="aff" rid="aff7-1741826710394305">7</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Eagle</surname><given-names>Kim A</given-names></name>
<xref ref-type="aff" rid="aff8-1741826710394305">8</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Goto</surname><given-names>Shinya</given-names></name>
<xref ref-type="aff" rid="aff9-1741826710394305">9</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mas</surname><given-names>Jean-Louis</given-names></name>
<xref ref-type="aff" rid="aff10-1741826710394305">10</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Montalescot</surname><given-names>Gilles</given-names></name>
<xref ref-type="aff" rid="aff11-1741826710394305">11</xref>
</contrib>
<contrib contrib-type="author">
<collab> (for the REACH Registry Investigators)</collab>
</contrib>
</contrib-group>
<aff id="aff1-1741826710394305"><label>1</label>Institut Pasteur de Lille, France; INSERM, U744, Lille, France.</aff>
<aff id="aff2-1741826710394305"><label>2</label>VA Boston Healthcare System, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA, USA.</aff>
<aff id="aff3-1741826710394305"><label>3</label>INSERM U698, Paris, France.</aff>
<aff id="aff4-1741826710394305"><label>4</label>Université Paris 7, Paris, France.</aff>
<aff id="aff5-1741826710394305"><label>5</label>Hôpital Bichat Claude Bernard, AP-HP, Paris, France.</aff>
<aff id="aff6-1741826710394305"><label>6</label>Centre d’Epidémiologie Clinique, INSERM U738, Paris, France.</aff>
<aff id="aff7-1741826710394305"><label>7</label>Cardiology Division, Emory University School of Medicine, Atlanta, GA, USA.</aff>
<aff id="aff8-1741826710394305"><label>8</label>University of Michigan Cardiovascular Center, Ann Arbor, MI, USA.</aff>
<aff id="aff9-1741826710394305"><label>9</label>Tokai University School of Medicine, Isehara, Japan.</aff>
<aff id="aff10-1741826710394305"><label>10</label>Paris-Descartes University, INSERM U894, Department of Neurology, Hôpital Sainte-Anne, Paris, France.</aff>
<aff id="aff11-1741826710394305"><label>11</label>Service de Cardiologie, Pitié-Salpétrière Hospital, AP-HP, INSERM U856, Université Paris 6, Paris, France.</aff>
<author-notes>
<corresp id="corresp1-1741826710394305">Jean Dallongeville, Institut Pasteur de Lille, INSERM U744, 1 rue du Pr Calmette, 59019 Lille Cedex, France Email: <email>jean.dallongeville@pasteur-lille.fr</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>19</volume>
<issue>2</issue>
<fpage>241</fpage>
<lpage>249</lpage>
<history>
<date date-type="received"><day>20</day><month>8</month><year>2010</year></date>
<date date-type="accepted"><day>14</day><month>11</month><year>2010</year></date>
</history>
<permissions>
<copyright-statement>© The European Society of Cardiology 2011 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="society">European Society of Cardiology</copyright-holder>
</permissions>
<abstract>
<p><bold>Aims:</bold> Obesity is frequent in type 2 diabetic patients with myocardial infarction (MI) or established cardiovascular disease. Earlier studies suggest that elevated body mass index (BMI) is associated with a favorable prognosis for persons with established vascular disease. We sought to analyse the associations between raised BMI and waist circumference with the 2-year event rate in type 2 diabetic patients with established vascular disease.</p>
<p><bold>Methods and results:</bold> Patients from the Reduction of Atherothrombosis for Continued Health (REACH) Registry, an international, prospective cohort of patients at high risk of atherothrombosis, were selected if they were diabetic and had established atherosclerotic arterial disease (<italic>n</italic> = 19,579). The main outcomes after 2-year follow-up were: all-cause death, cardiovascular death, MI, stroke, cardiovascular death/MI/stroke, and cardiovascular death/MI/stroke/rehospitalization. The rates of all-cause death, cardiovascular death, and cardiovascular death/MI/stroke decreased across increasing BMI quintile categories, whereas the same rates were stable across waist categories. The hazard ratios, adjusted for confounders, decreased significantly with increasing BMI for all-cause death (<italic>p</italic> &lt; 0.0001), cardiovascular death (<italic>p</italic> = 0.0009), cardiovascular death/MI/stroke (<italic>p</italic> = 0.0004), and all events (<italic>p</italic> = 0.002), but not for greater waist circumference.</p>
<p><bold>Conclusion:</bold> There is an apparent obesity paradox (better outcome with increasing obesity) when obesity is measured by BMI but not when measured by waist circumference in diabetic subjects.</p>
</abstract>
<kwd-group>
<kwd>Body mass index</kwd>
<kwd>cardiovascular outcomes</kwd>
<kwd>diabetes</kwd>
<kwd>vascular disease</kwd>
<kwd>waist circumference</kwd>
<kwd>obesity</kwd>
<kwd>metabolic syndrome</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1741826710394305" sec-type="intro"><title>Introduction</title>
<p>Obesity is a risk factor for increased mortality and cardiovascular disease in the general population.<sup><xref ref-type="bibr" rid="bibr1-1741826710394305">1</xref>,<xref ref-type="bibr" rid="bibr2-1741826710394305">2</xref></sup> In contrast, in patients with established vascular disease and those undergoing percutaneous coronary intervention or after an acute coronary syndrome, raised body mass index (BMI) appears to be associated with a favorable prognosis: the so-called ‘obesity paradox’.<sup><xref ref-type="bibr" rid="bibr3-1741826710394305">3</xref>,<xref ref-type="bibr" rid="bibr4-1741826710394305">4</xref></sup> A similar relationship is also reported in patients with heart failure, hypertension, and end-stage renal disease.<sup><xref ref-type="bibr" rid="bibr5-1741826710394305">5</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr7-1741826710394305">7</xref></sup></p>
<p>Type 2 diabetes is associated with increased coronary artery disease (CAD) risk in the general population.<sup><xref ref-type="bibr" rid="bibr8-1741826710394305">8</xref>,<xref ref-type="bibr" rid="bibr9-1741826710394305">9</xref></sup> The intensity of this risk, however, has been a matter of debate. One study reported that type 2 diabetic patients have the same risk of CAD death as non-diabetic subjects with a history of myocardial infarction (MI),<sup><xref ref-type="bibr" rid="bibr10-1741826710394305">10</xref>,<xref ref-type="bibr" rid="bibr11-1741826710394305">11</xref></sup> but this observation has not been confirmed in other studies.<sup><xref ref-type="bibr" rid="bibr12-1741826710394305">12</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr15-1741826710394305">15</xref></sup> Patients with diabetes have more extensive atherosclerosis, accelerated plaque progression, and a markedly increased risk of adverse events after MI or angioplasty.<sup><xref ref-type="bibr" rid="bibr16-1741826710394305">16</xref>,<xref ref-type="bibr" rid="bibr17-1741826710394305">17</xref></sup> The mechanism of this association is related to altered cardiovascular risk factors, as well as endothelial dysfunction, platelet aggregation, and inflammatory processes.</p>
<p>Obesity is frequent in type 2 diabetic patients with MI (reaching 54.8% in the USA) or established cardiovascular disease.<sup><xref ref-type="bibr" rid="bibr18-1741826710394305">18</xref></sup> To the best of our knowledge, the prognostic impact of total and abdominal obesity on recurrent events in diabetic patients with established atherothrombosis is unknown. The goal of the present study was to analyse the associations between raised BMI and waist circumference with the 2-year event rate in diabetic patients with established vascular disease.</p>
</sec>
<sec id="sec2-1741826710394305" sec-type="methods"><title>Methods</title>
<p>Full details of the rationale and design of the Reduction of Atherothrombosis for Continued Health (REACH) Registry have been described elsewhere.<sup><xref ref-type="bibr" rid="bibr19-1741826710394305">19</xref>,<xref ref-type="bibr" rid="bibr20-1741826710394305">20</xref></sup> The REACH Registry is a prospective, observational study of more than 68,000 outpatients from approximately 5000 sites in 44 countries. The study design was approved by the institutional review board in each participating country, and participants provided written informed consent to participate. Family and general practitioners made up 44% of the recruiting physicians; others were specialists in internal medicine (29%), cardiology (13%), neurology (9%), endocrinology (2%), general surgery (2%), and vascular disease (1%).<sup><xref ref-type="bibr" rid="bibr19-1741826710394305">19</xref>,<xref ref-type="bibr" rid="bibr20-1741826710394305">20</xref></sup></p>
<sec id="sec3-1741826710394305" sec-type="subjects"><title>Subjects</title>
<p>Physician participating to the study diagnosed and reported diabetes from their patients’ records. In the present analysis, we considered all diabetic patients with established vascular disease. Our final sample consisted of 19,579 subjects. Patients enrolled were aged ≥45 years with at least one of the following: (1) CAD (angina, MI, coronary angioplasty, stent implantation, or bypass surgery); (2) cerebrovascular disease (CVD) (ischaemic stroke or transient ischaemic attack (TIA)); or (3) peripheral arterial disease [PAD; historical or current intermittent claudication associated with ankle-brachial index (ABI) &lt;0.9]. Patients already in a clinical trial, hospitalized patients, and those who might have difficulty returning for a follow-up visit were excluded. Patients were evaluated at baseline for a range of demographic, medical, and laboratory characteristics, before being re-evaluated annually for up to 48 months post baseline to ascertain whether they experienced any clinical events or hospitalizations.</p>
</sec>
<sec id="sec4-1741826710394305"><title>Definition of cardiovascular risk factors</title>
<p>Data were collected using a standardized international case report form, which was completed at the study visit. Baseline height, weight, waist circumference, systolic and diastolic blood pressure, and available fasting glucose and cholesterol levels were obtained. From these data, baseline demographic and risk factor characteristics were analysed. Current smoking was defined as ≥5 cigarettes/day on average within the month before entry into the REACH Registry.</p>
</sec>
<sec id="sec5-1741826710394305"><title>Follow-up</title>
<p>Follow-up data (at 24 months) were collected from participating physicians from medical records, and included clinical outcomes, treatment, and physical or biological data.<sup><xref ref-type="bibr" rid="bibr21-1741826710394305">21</xref></sup> Although events were not adjudicated, reports of ischaemic stroke and TIA had to be sourced from a neurologist or hospital to ensure a reliable diagnosis. Endpoint definitions were: (a) all-cause death; (b) cardiovascular death, including fatal stroke, fatal MI, and other cardiovascular death (including other death of cardiac origin; pulmonary embolism; any sudden death; death following a vascular operation, vascular procedure, or amputation (except for trauma or malignancy); death attributed to heart failure; death following a visceral or limb infarction, and any other death that could not be attributed definitely to a non-vascular cause or haemorrhage); (c) non-fatal MI; (d) non-fatal stroke; (e) cardiovascular death/MI/stroke; and (f) cardiovascular death/MI/stroke/rehospitalization for an atherothrombotic event.</p>
</sec>
<sec id="sec6-1741826710394305"><title>Statistical analysis</title>
<p>Continuous variables are expressed as mean ±standard deviation. Categorical variables are expressed as frequencies and percentages. Patients were separated into quintiles of BMI and waist circumference distribution. Age- and sex-related event rates were computed for each quintile of distribution. Multivariable hazard ratios (HRs) were calculated with Cox regression using the second quintile as the reference group. Covariables were selected <italic>a priori</italic> and included: age, sex, smoking, hypertension, hypercholesterolaemia, symptomatic disease, number of affected vascular beds, physician’s medical specialty, lipid-lowering therapy, antihypertensive agents, antiplatelets, beta-blockers, oral antidiabetic drugs, and insulin. Trend analyses were performed using BMI or waist categories as continuous variables. Statistical analyses were conducted using SAS version 9.1 software (SAS Institute Inc, Cary, NC).</p>
</sec>
</sec>
<sec id="sec7-1741826710394305" sec-type="results"><title>Results</title>
<sec id="sec8-1741826710394305"><title>Baseline characteristics according to BMI</title>
<p>The baseline demographics, clinical characteristics, and treatments of the 19,579 diabetic patients with established vascular disease are presented in <xref ref-type="table" rid="table1-1741826710394305">Table 1</xref> by quintile of BMI. The higher BMI quintiles had a lower mean age (<italic>p</italic> &lt; 0.0001), but more women (<italic>p</italic> &lt; 0.0001), Caucasians (<italic>p</italic> &lt; 0.0001), former smokers (<italic>p</italic> &lt; 0.0001), and patients with a history of raised blood pressure (<italic>p</italic> &lt; 0.0001). Mean systolic and diastolic blood pressure levels (<italic>p</italic> &lt; 0.0001), and concentrations of triglycerides (<italic>p</italic> &lt; 0.0001) and glycaemia (<italic>p</italic> = 0.0005) (but not cholesterol) were higher in the upper than the lower quintile of BMI distribution. With respect to vascular disease, there were more patients with CAD (<italic>p</italic> &lt; 0.0001) than with stroke or PAD, and these patients less frequently had multiple vascular bed disease (<italic>p</italic> &lt; 0.0028) in the highest than lowest quintile of BMI distribution. In general, patients in the higher BMI quintiles received more medications than those in the lower BMI groups. Fewer obese patients achieved target blood pressure, triglycerides, and glycaemia goals, but cholesterol levels were similar across quintiles.
<table-wrap id="table1-1741826710394305" position="float"><label>Table 1.</label><caption><p>Characteristics at baseline and treatment of diabetic patients with symptomatic disease (<italic>n</italic> = 19,579) according to body mass index and waist circumference quintiles</p></caption>
<graphic alternate-form-of="table1-1741826710394305" xlink:href="10.1177_1741826710394305-table1a.tif"/>
<graphic alternate-form-of="table1-1741826710394305" xlink:href="10.1177_1741826710394305-table1b.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2"/><th colspan="6">Body mass index quintiles (kg/m<sup>2</sup>)<hr/></th>
<th colspan="6">Waist circumference quintiles (cm)<hr/></th></tr>
<tr><th>Q1 (24.32)</th>
<th>Q2 (24.33–26.93)</th>
<th>Q3 (26.94–29.43)</th>
<th>Q4 (29.44–33.06)</th>
<th>Q5 (33.07)</th>
<th><italic>p</italic> (trend)</th>
<th>Q1 (88.0)</th>
<th>Q2 (88.1–96.0)</th>
<th>Q3 (96.1–103.0)</th>
<th>Q4 (103.1–111.8)</th>
<th>Q5 (111.9)</th>
<th><italic>p</italic> (trend)</th></tr></thead>
<tbody align="left">
<tr>
<td><italic>n</italic></td>
<td>3912</td>
<td>3931</td>
<td>3914</td>
<td>3912</td>
<td>3910</td>
<td/>
<td>3886</td>
<td>3519</td>
<td>3821</td>
<td>3637</td>
<td>3623</td>
<td/></tr>
<tr>
<td>Age (years)</td>
<td>70.4 ± 9.5</td>
<td>69.7 ± 9.3</td>
<td>68.7 ± 9.3</td>
<td>67.6 ± 9.4</td>
<td>65.6 ± 9.1</td>
<td>&lt;0.0001</td>
<td>69.5 ± 9.6</td>
<td>68.7 ± 9.6</td>
<td>68.9 ± 9.4</td>
<td>68.1 ± 9.3</td>
<td>66.8 ± 9.2</td>
<td>&lt;0.0001</td></tr>
<tr>
<td>Female</td>
<td>35.6</td>
<td>30.8</td>
<td>29.3</td>
<td>33.2</td>
<td>43.2</td>
<td>&lt;0.0001</td>
<td>47.1</td>
<td>33.5</td>
<td>31.7</td>
<td>28.2</td>
<td>30.3</td>
<td>&lt;0.0001</td></tr>
<tr>
<td>Ethnic origin</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>&lt;0.0001</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>&lt;0.0001</td></tr>
<tr>
<td> Caucasian</td>
<td>38.1</td>
<td>56.3</td>
<td>66.0</td>
<td>73.3</td>
<td>79.4</td>
<td/>
<td>35.7</td>
<td>53.6</td>
<td>67.0</td>
<td>76.6</td>
<td>80.9</td>
<td/></tr>
<tr>
<td> Hispanic</td>
<td>5.1</td>
<td>5.9</td>
<td>6.5</td>
<td>6.2</td>
<td>4.8</td>
<td/>
<td>5.3</td>
<td>6.4</td>
<td>6.9</td>
<td>5.8</td>
<td>4.5</td>
<td/></tr>
<tr>
<td> East Asian</td>
<td>37.0</td>
<td>20.8</td>
<td>10.6</td>
<td>5.2</td>
<td>1.6</td>
<td/>
<td>39.4</td>
<td>22.2</td>
<td>9.0</td>
<td>3.8</td>
<td>1.3</td>
<td/></tr>
<tr>
<td> South Asian</td>
<td>2.8</td>
<td>2.1</td>
<td>1.7</td>
<td>1.2</td>
<td>0.4</td>
<td/>
<td>2.9</td>
<td>2.1</td>
<td>1.8</td>
<td>1.0</td>
<td>0.7</td>
<td/></tr>
<tr>
<td> Other Asian</td>
<td>12.1</td>
<td>8.2</td>
<td>5.8</td>
<td>3.9</td>
<td>2.2</td>
<td/>
<td>11.4</td>
<td>8.4</td>
<td>6.1</td>
<td>3.7</td>
<td>2.0</td>
<td/></tr>
<tr>
<td> Black</td>
<td>2.7</td>
<td>3.0</td>
<td>5.0</td>
<td>6.4</td>
<td>8.7</td>
<td/>
<td>3.1</td>
<td>4.1</td>
<td>5.4</td>
<td>5.5</td>
<td>6.5</td>
<td/></tr>
<tr>
<td> Other</td>
<td>2.3</td>
<td>3.6</td>
<td>4.4</td>
<td>4.0</td>
<td>2.9</td>
<td/>
<td>2.2</td>
<td>3.2</td>
<td>3.9</td>
<td>3.6</td>
<td>4.3</td>
<td/></tr>
<tr>
<td>Smoking</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>&lt;0.0001</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>&lt;0.0001</td></tr>
<tr>
<td> Current</td>
<td>13.7</td>
<td>13.0</td>
<td>12.6</td>
<td>11.5</td>
<td>12.0</td>
<td/>
<td>12.7</td>
<td>13.0</td>
<td>12.1</td>
<td>12.5</td>
<td>12.3</td>
<td/></tr>
<tr>
<td> Former</td>
<td>39.0</td>
<td>43.9</td>
<td>45.6</td>
<td>48.4</td>
<td>45.6</td>
<td/>
<td>34.4</td>
<td>42.4</td>
<td>46.4</td>
<td>49.3</td>
<td>51.1</td>
<td/></tr>
<tr>
<td> Never</td>
<td>47.3</td>
<td>43.1</td>
<td>41.8</td>
<td>40.1</td>
<td>42.5</td>
<td/>
<td>52.9</td>
<td>44.6</td>
<td>41.5</td>
<td>38.2</td>
<td>36.6</td>
<td/></tr>
<tr>
<td>History of HBP</td>
<td>80.1</td>
<td>84.6</td>
<td>87.5</td>
<td>90.2</td>
<td>92.8</td>
<td>&lt;0.0001</td>
<td>81.3</td>
<td>85.2</td>
<td>87.7</td>
<td>89.4</td>
<td>91.3</td>
<td>&lt;0.0001</td></tr>
<tr>
<td>DBP (mmHg)</td>
<td>75.7 ± 11.3</td>
<td>77.0 ± 11.2</td>
<td>78.4 ± 11.3</td>
<td>78.6 ± 11.7</td>
<td>77.9 ± 11.5</td>
<td>&lt;0.0001</td>
<td>76.5 ± 11.6</td>
<td>77.5 ± 11.2</td>
<td>77.6 ± 11.4</td>
<td>77.9 ± 11.4</td>
<td>78.3 ± 11.7</td>
<td>&lt;0.0001</td></tr>
<tr>
<td>SBP (mmHg)</td>
<td>136.2 ± 20.1</td>
<td>137.6 ± 19.0</td>
<td>138.9 ± 19.9</td>
<td>138.8 ± 19.7</td>
<td>137.9 ± 19.1</td>
<td>&lt;0.0001</td>
<td>137.2 ± 20.0</td>
<td>137.7 ± 19.7</td>
<td>138.0 ± 19.5</td>
<td>137.7 ± 19.2</td>
<td>138.9 ± 19.4</td>
<td>0.0024</td></tr>
<tr>
<td>Total cholesterol  &gt;200 mg/dl</td>
<td>34.4</td>
<td>34.1</td>
<td>35.5</td>
<td>34.6</td>
<td>32.9</td>
<td>0.26</td>
<td>37.5</td>
<td>34.1</td>
<td>33.3</td>
<td>32.9</td>
<td>33.3</td>
<td>0.0005</td></tr>
<tr>
<td>Total cholesterol (mg/dl)</td>
<td>188.3 ± 45.8</td>
<td>187.3 ± 48.2</td>
<td>190.5 ± 51.0</td>
<td>189.2 ± 50.4</td>
<td>187.4 ± 48.3</td>
<td>0.039</td>
<td>191.4 ± 47.0</td>
<td>188.1 ± 47.7</td>
<td>188.2 ± 50.1</td>
<td>187.3 ± 50.4</td>
<td>187.9 ± 49.1</td>
<td>0.009</td></tr>
<tr>
<td>Total triglycerides  &gt;150 mg/dl</td>
<td>37.1</td>
<td>44.8</td>
<td>51.0</td>
<td>55.1</td>
<td>59.9</td>
<td>&lt;0.0001</td>
<td>39.6</td>
<td>43.8</td>
<td>50.0</td>
<td>55.8</td>
<td>58.9</td>
<td>&lt;0.0001</td></tr>
<tr>
<td>Total triglycerides (mg/dl)</td>
<td>149.6 ± 94.0</td>
<td>163.1 ± 98.3</td>
<td>177.3 ± 105.5</td>
<td>187.3 ± 110.8</td>
<td>197.1 ± 117.1</td>
<td>&lt;0.0001</td>
<td>153.5 ± 95.0</td>
<td>163.1 ± 99.3</td>
<td>175.6 ± 105.5</td>
<td>186.3 ± 110.0</td>
<td>196.5 ± 116.7</td>
<td>&lt;0.0001</td></tr>
<tr>
<td>Raised glycaemia  (≥126 mg/dl)</td>
<td>67.4</td>
<td>71.3</td>
<td>75.0</td>
<td>75.7</td>
<td>78.0</td>
<td>&lt;0.0001</td>
<td>69.1</td>
<td>71.1</td>
<td>72.3</td>
<td>75.9</td>
<td>78.5</td>
<td>&lt;0.0001</td></tr>
<tr>
<td>Glycaemia (mg/dl)</td>
<td>144.8 ± 56.3</td>
<td>143.7 ± 50.7</td>
<td>144.7 ± 50.7</td>
<td>145.9 ± 53.1</td>
<td>149.1 ± 56.7</td>
<td>0.0005</td>
<td>144.7 ± 55.2</td>
<td>142.7 ± 50.6</td>
<td>144.4 ± 53.0</td>
<td>145.8 ± 51.9</td>
<td>150.2 ± 55.4</td>
<td>&lt;0.0001</td></tr>
<tr>
<td>Number of affected  vessel locations</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>0.0028</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>&lt;0.0001</td></tr>
<tr>
<td> 1</td>
<td>77.5</td>
<td>77.3</td>
<td>75.6</td>
<td>76.7</td>
<td>78.9</td>
<td/>
<td>79.8</td>
<td>78.5</td>
<td>75.9</td>
<td>76.1</td>
<td>75.0</td>
<td/></tr>
<tr>
<td> 2</td>
<td>19.2</td>
<td>20.3</td>
<td>21.4</td>
<td>21.0</td>
<td>18.7</td>
<td/>
<td>18.1</td>
<td>18.8</td>
<td>21.2</td>
<td>21.3</td>
<td>22.0</td>
<td/></tr>
<tr>
<td> 3</td>
<td>3.3</td>
<td>2.4</td>
<td>3.0</td>
<td>2.3</td>
<td>2.4</td>
<td/>
<td>2.1</td>
<td>2.7</td>
<td>2.9</td>
<td>2.6</td>
<td>3.0</td>
<td/></tr>
<tr>
<td>Disease locations</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td> CAD</td>
<td>64.6</td>
<td>71.7</td>
<td>75.5</td>
<td>77.6</td>
<td>81.2</td>
<td>&lt;0.0001</td>
<td>66.0</td>
<td>70.5</td>
<td>75.4</td>
<td>78.3</td>
<td>80.5</td>
<td>&lt;0.0001</td></tr>
<tr>
<td> Stroke</td>
<td>41.5</td>
<td>34.9</td>
<td>34.0</td>
<td>31.0</td>
<td>27.8</td>
<td>&lt;0.0001</td>
<td>40.1</td>
<td>36.7</td>
<td>33.5</td>
<td>30.0</td>
<td>29.3</td>
<td>&lt;0.0001</td></tr>
<tr>
<td> PAD</td>
<td>19.6</td>
<td>18.6</td>
<td>17.9</td>
<td>17.1</td>
<td>14.5</td>
<td>&lt;0.0001</td>
<td>16.1</td>
<td>17.0</td>
<td>18.2</td>
<td>18.2</td>
<td>18.1</td>
<td>0.064</td></tr>
<tr>
<td>Medication</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>&lt;0.0001</td></tr>
<tr>
<td> Antiplatelets</td>
<td>82.8</td>
<td>84.3</td>
<td>84.1</td>
<td>83.7</td>
<td>82.0</td>
<td>0.034</td>
<td>83.3</td>
<td>84.5</td>
<td>84.1</td>
<td>83.1</td>
<td>82.0</td>
<td>0.047</td></tr>
<tr>
<td> Lipid-lowering agents</td>
<td>64.9</td>
<td>74.6</td>
<td>79.4</td>
<td>81.8</td>
<td>83.3</td>
<td>&lt;0.0001</td>
<td>67.3</td>
<td>74.6</td>
<td>78.9</td>
<td>81.8</td>
<td>81.9</td>
<td>&lt;0.0001</td></tr>
<tr>
<td> Beta-blockers</td>
<td>39.7</td>
<td>49.4</td>
<td>54.2</td>
<td>57.3</td>
<td>59.8</td>
<td>&lt;0.0001</td>
<td>61.9</td>
<td>68.8</td>
<td>73.4</td>
<td>76.1</td>
<td>75.7</td>
<td>&lt;0.0001</td></tr>
<tr>
<td> ACE inhibitors</td>
<td>41.1</td>
<td>49.3</td>
<td>53.6</td>
<td>55.2</td>
<td>56.3</td>
<td>&lt;0.0001</td>
<td>10.1</td>
<td>12.1</td>
<td>13.8</td>
<td>14.3</td>
<td>15.7</td>
<td>&lt;0.0001</td></tr>
<tr>
<td> Angiotensin II blockers</td>
<td>24.3</td>
<td>24.6</td>
<td>24.1</td>
<td>26.4</td>
<td>28.0</td>
<td>0.001</td>
<td>39.9</td>
<td>48.9</td>
<td>52.7</td>
<td>57.2</td>
<td>57.4</td>
<td>&lt;0.0001</td></tr>
<tr>
<td> Other antihypertensives</td>
<td>8.8</td>
<td>10.1</td>
<td>11.1</td>
<td>12.6</td>
<td>14.5</td>
<td>&lt;0.0001</td>
<td>9.2</td>
<td>9.2</td>
<td>11.6</td>
<td>12.6</td>
<td>14.1</td>
<td>&lt;0.0001</td></tr>
<tr>
<td> Antidiabetics</td>
<td>85.5</td>
<td>87.0</td>
<td>87.7</td>
<td>88.4</td>
<td>91.4</td>
<td>&lt;0.0001</td>
<td>85.8</td>
<td>86.5</td>
<td>88.3</td>
<td>88.6</td>
<td>90.3</td>
<td>&lt;0.0001</td></tr>
<tr>
<td> Insulin</td>
<td>23.1</td>
<td>25.3</td>
<td>26.3</td>
<td>30.2</td>
<td>37.3</td>
<td>&lt;0.0001</td>
<td>23.5</td>
<td>23.1</td>
<td>27.4</td>
<td>30.4</td>
<td>35.8</td>
<td>&lt;0.0001</td></tr>
<tr>
<td> Biguanides</td>
<td>31.1</td>
<td>34.8</td>
<td>39.5</td>
<td>40.8</td>
<td>43.3</td>
<td>&lt;0.0001</td>
<td>31.7</td>
<td>35.6</td>
<td>38.8</td>
<td>41.6</td>
<td>42.4</td>
<td>&lt;0.0001</td></tr>
<tr>
<td> Sulphonylureas</td>
<td>45.5</td>
<td>44.7</td>
<td>43.3</td>
<td>42.0</td>
<td>41.3</td>
<td>0.0006</td>
<td>44.8</td>
<td>45.1</td>
<td>44.7</td>
<td>41.3</td>
<td>41.1</td>
<td>&lt;0.0001</td></tr>
<tr>
<td> Thiazol</td>
<td>9.5</td>
<td>11.2</td>
<td>13.8</td>
<td>16.5</td>
<td>24.2</td>
<td>&lt;0.0001</td>
<td>10.8</td>
<td>11.4</td>
<td>15.5</td>
<td>16.9</td>
<td>19.7</td>
<td>&lt;0.0001</td></tr>
<tr>
<td> Other</td>
<td>14.4</td>
<td>11.6</td>
<td>9.9</td>
<td>9.1</td>
<td>8.7</td>
<td>&lt;0.0001</td>
<td>14.6</td>
<td>11.1</td>
<td>9.8</td>
<td>9.3</td>
<td>9.0</td>
<td>&lt;0.0001</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1741826710394305"><p>Values are means ± SD or %.</p></fn>
<fn id="table-fn2-1741826710394305"><p>CAD, coronary artery disease; DBP, diastolic blood pressure; HBP, high blood pressure; PAD, peripheral arterial disease; Q, quintile; SBP, systolic blood pressure.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec9-1741826710394305"><title>Baseline characteristics according to waist circumference</title>
<p>Baseline demographics, clinical characteristics and treatments by quintile of waist circumference are also presented in <xref ref-type="table" rid="table1-1741826710394305">Table 1</xref>. The mean age was lower (<italic>p</italic> &lt; 0.0001) and there were more Caucasians (<italic>p</italic> &lt; 0.0001) and former smokers (<italic>p</italic> &lt; 0.0001) in the higher quintiles of waist distribution. In contrast, there were fewer women (<italic>p</italic> &lt; 0.0001) in the highest quintile than in the lowest. Increased waist circumference was associated with a history of hypertension (<italic>p</italic> &lt; 0.0001). Mean blood pressure (<italic>p</italic> = 0.0024), triglycerides (<italic>p</italic> &lt; 0.0001) and glycaemia (<italic>p</italic> &lt; 0.0001), but not cholesterol levels, were higher in the upper than in the lower quintile of waist circumference distribution. With respect to vascular disease, there were more patients with CAD (<italic>p</italic> &lt; 0.0001) and fewer with stroke (<italic>p</italic> &lt; 0.0001) in the highest quintiles of waist distribution. In contrast to BMI, these patients more frequently had multiple vascular bed disease (<italic>p</italic> &lt; 0.0001) in the highest than in the lowest quintile of waist distribution. Patients in the higher waist quintiles received more medications than those in the lower waist groups. Subjects with abdominal obesity were less likely to achieve target blood pressure, triglycerides, and glycaemia goals but more likely to reach cholesterol goals.</p>
</sec>
<sec id="sec10-1741826710394305"><title>Relationship between BMI/waist circumference and event rates</title>
<p><xref ref-type="fig" rid="fig1-1741826710394305">Figure 1</xref> shows the age- and sex-adjusted event rates across quintiles of BMI and waist circumference. The rates of all-cause death (<italic>p</italic> trend &lt; 0.005), non-fatal stroke (<italic>p</italic> &lt; 0.008), and cardiovascular death/MI/stroke (<italic>p</italic> &lt; 0.002) decreased across increasing BMI categories. The rates of all events (including rehospitalization) rose from the first quintile to the third and then decreased. In contrast, the rates of all-cause death (<italic>p</italic> trend &lt;0.05) and all events (<italic>p</italic> &lt; 0.0007) rose between the lowest and highest quintile of waist distribution. There were no other statistically significant trends.
<fig id="fig1-1741826710394305" position="float"><label>Figure 1.</label><caption><p>Two-year event rates adjusted for age and sex according to body mass index (A) and waist circumference (B) quintiles in symptomatic and diabetic patients  CV, cardiovascular; MI, myocardial infarction.</p></caption><graphic xlink:href="10.1177_1741826710394305-fig1.tif"/></fig></p>
</sec>
<sec id="sec11-1741826710394305"><title>Adjusted HRs of the relationship between BMI/waist circumference and event rates</title>
<p>Compared with the second quintile of BMI distribution (which was used as a reference; HR defined as 1), patients in the lowest quintile of BMI distribution had a higher risk of all-cause death, cardiovascular death, and cardiovascular death/MI/stroke (<xref ref-type="table" rid="table2-1741826710394305">Table 2</xref>). Increasing BMI was associated with decreasing trends in all-cause death, cardiovascular death, non-fatal MI, cardiovascular death/MI/stroke and all events (including rehospitalization). In contrast, there were no associations between increasing waist circumference and adjusted HRs of any of these events.
<table-wrap id="table2-1741826710394305" position="float"><label>Table 2.</label><caption><p>Hazard ratios and 95% CI of events according to body mass index and waist circumference quintiles adjusted for age, sex, geographic area, smoking, hypertension, hypercholesterolaemia, symptomatic, number of vascular beds, specialty, lipid-lowering agents, antihypertensive agents, antiplatelets, beta-blockers, oral antidiabetic agents, and insulin for symptomatic and diabetic patients</p></caption>
<graphic alternate-form-of="table2-1741826710394305" xlink:href="10.1177_1741826710394305-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2"/><th colspan="6">Body mass index quintiles (kg/m<sup>2</sup>)<hr/></th>
<th colspan="6">Waist circumference quintiles (cm)<sup><xref ref-type="table-fn" rid="table-fn5-1741826710394305">a</xref></sup><hr/></th></tr>
<tr><th>Q1 (24.32)</th>
<th>Q2 (24.33– 26.93)</th>
<th>Q3 (26.94–29.43)</th>
<th>Q4 (29.44–33.06)</th>
<th>Q5 (33.07)</th>
<th><italic>p</italic> (trend)</th>
<th>Q1 (88.0)</th>
<th>Q2 (88.1– 96.0)</th>
<th>Q3 (96.1–103.0)</th>
<th>Q4 (103.1–111.8)</th>
<th>Q5 (111.9)</th>
<th><italic>p</italic> (trend)</th></tr></thead>
<tbody align="left">
<tr>
<td><italic>n</italic></td>
<td>3912</td>
<td>3931</td>
<td>3914</td>
<td>3912</td>
<td>3910</td>
<td/>
<td>3886</td>
<td>3519</td>
<td>3821</td>
<td>3637</td>
<td>3623</td>
<td/></tr>
<tr>
<td>All-cause death</td>
<td>1.38 (1.16–1.63)</td>
<td>1</td>
<td>0.96 (0.80–1.15)</td>
<td>0.92 (0.76–1.11)</td>
<td>0.86 (0.71–1.05)</td>
<td>&lt;0.0001</td>
<td>1.18 (0.97–1.43)</td>
<td>1</td>
<td>1.13 (0.93–1.36)</td>
<td>1.07 (0.88–1.30)</td>
<td>1.07 (0.88–1.31)</td>
<td>0.54</td></tr>
<tr>
<td>CV death</td>
<td>1.35 (1.09–1.67)</td>
<td>1</td>
<td>0.96 (0.77–1.20)</td>
<td>0.84 (0.66–1.06)</td>
<td>0.97 (0.77–1.23)</td>
<td>0.0009</td>
<td>1.10 (0.86–1.39)</td>
<td>1</td>
<td>1.04 (0.83–1.31)</td>
<td>0.96 (0.76–1.22)</td>
<td>1.00 (0.79–1.27)</td>
<td>0.87</td></tr>
<tr>
<td>Non-fatal MI</td>
<td>1.22 (0.91–1.63)</td>
<td>1</td>
<td>0.93 (0.69–1.25)</td>
<td>0.98 (0.73–1.30)</td>
<td>0.70 (0.51–1.95)</td>
<td>0.017</td>
<td>1.37 (1.00–1.88)</td>
<td>1</td>
<td>1.07 (0.78–1.47)</td>
<td>1.17 (0.86–1.60)</td>
<td>0.86 (0.62–1.21)</td>
<td>0.060</td></tr>
<tr>
<td>Non-fatal stroke</td>
<td>0.97 (0.75–1.24)</td>
<td>1</td>
<td>0.93 (0.72–1.21)</td>
<td>1.02 (0.79–1.33)</td>
<td>0.79 (0.59–1.06)</td>
<td>0.45</td>
<td>0.91 (0.71–1.18)</td>
<td>1</td>
<td>0.85 (0.65–1.12)</td>
<td>0.99 (0.76–1.30)</td>
<td>0.94 (0.71–1.25)</td>
<td>0.77</td></tr>
<tr>
<td>CV death/MI/stroke</td>
<td>1.17 (1.01–1.35)</td>
<td>1</td>
<td>0.92 (0.79–1.07)</td>
<td>0.89 (0.76–1.04)</td>
<td>0.82 (0.70–0.97)</td>
<td>0.0004</td>
<td>1.08 (0.92–1.27)</td>
<td>1</td>
<td>1.00 (0.86–1.17)</td>
<td>1.10 (0.86–1.18)</td>
<td>0.93 (0.79–1.10)</td>
<td>0.53</td></tr>
<tr>
<td>CV death/MI/stroke/  hospitalization  (all events)</td>
<td>1.01 (0.92–1.11)</td>
<td>1</td>
<td>0.96 (0.87–1.05)</td>
<td>0.92 (0.83–1.01)</td>
<td>0.83 (0.75–0.92)</td>
<td>0.002</td>
<td>1.06 (0.96–1.17)</td>
<td>1</td>
<td>0.99 (0.90–1.09)</td>
<td>0.97 (0.88–1.08)</td>
<td>0.90 (0.81–1.00)</td>
<td>0.061</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1741826710394305"><p>Values are hazard ratios (95% CI).</p></fn>
<fn id="table-fn4-1741826710394305"><p>CV, cardiovascular; HR, hazard ratio; MI, myocardial infarction; Q, quintile.</p></fn>
<fn id="table-fn5-1741826710394305"><label>a</label><p>Missing data for waist circumference for 1093 patients.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Subgroup analyses for cardiovascular death/MI/stroke are presented in <xref ref-type="fig" rid="fig2-1741826710394305">Figure 2</xref>. There was no evidence for heterogeneity between sex, age, ethnicity, smoking, hypertension, hypercholesterolaemia, raised triglycerides, and affected vascular bed groups. Results for additional end-points are presented in the supplementary material online appendix.
<fig id="fig2-1741826710394305" position="float"><label>Figure 2.</label><caption><p>Hazard ratios and 95% confidence intervals for cardiovascular death/myocardial infarction/stroke per one standard deviation increase in body mass index or waist circumference CAD, coronary artery disease; HBP, high blood pressure; PAD, peripheral arterial disease; TG, triglycerides.</p></caption><graphic xlink:href="10.1177_1741826710394305-fig2.tif"/></fig></p>
</sec>
</sec>
<sec id="sec12-1741826710394305" sec-type="discussion"><title>Discussion</title>
<p>In the present study, we have analysed the relationships between BMI and waist circumference with 2-year rates of death, cardiovascular events, and rehospitalization in 19,579 diabetic patients with established vascular disease. Greater BMI was associated with better prognosis for all-cause death, cardiovascular death, and composite end-points including rehospitalization. In contrast, waist circumference, a marker of visceral adiposity, showed no association with outcomes. These results extend the observation of an ‘obesity paradox’ to diabetic patients and show that waist circumference measurement does not predict vascular outcomes reliably in diabetic patients with established vascular disease.</p>
<p>BMI was inversely associated with age- and sex-adjusted crude rates of death and cardiovascular events (<xref ref-type="fig" rid="fig1-1741826710394305">Figure 1</xref>). Adjustment for confounders attenuated this association, suggesting that covariables such as age, sex, smoking, risk factors, and treatment contribute to the paradoxical prognosis in obese diabetic subjects. Indeed, the characteristics of the subjects in the highest quintiles of BMI distribution differed greatly from those of the subjects in the lowest quintiles. Similar differences between obese and lean patients have been reported in other databases reporting a paradoxical association between BMI and outcomes in patients with established CAD.<sup><xref ref-type="bibr" rid="bibr22-1741826710394305">22</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr24-1741826710394305">24</xref></sup> Overall, our findings in diabetic patients do not differ markedly from those of earlier studies in patients with hypertension<sup><xref ref-type="bibr" rid="bibr25-1741826710394305">25</xref></sup> or in non-selected CAD patients.<sup><xref ref-type="bibr" rid="bibr3-1741826710394305">3</xref>,<xref ref-type="bibr" rid="bibr4-1741826710394305">4</xref></sup> In the latter studies, diabetes was an important confounder associated with both obesity and prognosis. Our results suggest that diabetes is not likely to affect the relationship in CAD patients.</p>
<p>Waist circumference is strongly correlated with intra-abdominal adipose tissue and metabolic disorders and, in the general population, is associated with CAD events occurrence.<sup><xref ref-type="bibr" rid="bibr26-1741826710394305">26</xref></sup> In the present study, waist circumference showed neither an inverse relationship with cardiovascular event rates nor a positive relationship, despite being associated with metabolic disorders such as hypertriglyceridaemia, dyslipidaemia, and hypertension. Earlier studies that assessed the prognosis of CAD patients in relation to waist girth or waist-to-hip ratio have found mixed results: no associations were found between waist girth and outcomes in some<sup><xref ref-type="bibr" rid="bibr27-1741826710394305">27</xref>,<xref ref-type="bibr" rid="bibr28-1741826710394305">28</xref></sup> but not all<sup><xref ref-type="bibr" rid="bibr29-1741826710394305">29</xref>,<xref ref-type="bibr" rid="bibr30-1741826710394305">30</xref></sup> studies.</p>
<p>Several hypotheses have been proposed to explain the inverse association between BMI and cardiovascular events. From a pathophysiological point of view, there is no doubt that adipose tissue accumulation triggers an inflammatory response that is responsible for altered lipid and glucose metabolism and vascular damage. In the general population, BMI and waist circumference are convenient surrogate measures of body fat, but this may not be the case (particularly for BMI) in patients with established CAD. Indeed, sarcopenia, muscle wasting, and inanition are associated with reduced BMI and poor prognosis and may be more common in older patients with established atherosclerosis.<sup><xref ref-type="bibr" rid="bibr3-1741826710394305">3</xref></sup> It has also been proposed that patients with higher BMI have a greater metabolic reserve that protects them from complications in the context of heart failure. Finally, given their worse cardiometabolic risk profile, obese subjects may be more likely to receive care, as suggested by the larger proportion of obese subjects receiving cardiovascular treatment. Although statistical adjustments were performed, the likelihood of residual confounding effects in this observational study is not negligible. Furthermore, the differences in baseline characteristics could hamper the possibility of comparing the prognosis. Even if statistical adjustments were used to control confounders, the likely residual effect is important.</p>
<p>The present study has various strengths and limitations. The REACH Registry is a large cohort of 19,579 diabetic patients with atherothrombosis receiving contemporary therapies. However, given its observational design, no causal inference can be drawn from the conclusions. The 2-year follow-up rate was high, with data collected from &gt;95% of patients, with no noticeable dropout. However, 2 years is a relatively short time period, and with much longer follow-up a relationship may have emerged between waist circumference and adverse ischaemic outcomes. Most patients were receiving recommended treatments in line with current guidelines for diabetes care, but less than half reached treatment goals for glycaemia. However, as with most observational studies, the baseline characteristics of the subjects were not matched. Changes in body weight after the index event were not recorded, making it impossible to assess potential effects of weight change (intentional or unintentional) on prognosis.</p>
<p>The clinical implications of these findings are that BMI and waist measurements cannot be used as simple markers to assess the risk of future complications in diabetic patients with established vascular diseases. Additionally, pharmacotherapies that are designed to decrease weight should not be assumed to reduce clinical cardiovascular events. Furthermore, owing to the possibility of residual confounders, one should not conclude that weight reduction is unnecessary or harmful in diabetic patients with established coronary heart disease. Intentional weight loss is associated with an improvement in cardiovascular risk profile and better long-term prognosis in obese subjects and diabetic patients with coronary heart disease.</p>
</sec>
</body>
<back>
<ack><title>Acknowledgements</title>
<p>The REACH Registry is endorsed by the World Heart Federation. A complete list of REACH investigators is accessible in <italic>JAMA</italic> 2006; 295: 180–9. The REACH Registry enforces a no-ghost-writing policy. This manuscript was written and edited by the authors, who take full responsibility for its content. The first draft was written by Jean Dallongeville. We thank the Editorial Support Group for assistance with coordinating revisions and providing editorial help in preparing this manuscript, including editing, checking content and language, formatting, referencing and preparing tables and figures. The Hôpital Bichat verified all statistical analyses. We thank Blandine Pasquet for statistical analyses.</p>
<p>The sponsors provide logistical support. All the publication activity is controlled by the REACH Registry Global Publication Committee (Ph Gabriel Steg, Deepak L Bhatt, Mark Alberts, Ralph D’Agostino, Kim Eagle, Shinya Goto, Alan T Hirsch, Chiau-Suong Liau, Jean-Louis Mas, E Magnus Ohman, Joachim Röther, Sidney C Smith, Peter WF Wilson).</p></ack>
<sec id="sec13-1741826710394305"><title>Funding</title>
<p>The REACH Registry is sponsored by Sanofi Aventis, Bristol-Myers Squibb, and the Waksman Foundation (Tokyo, Japan).</p>
</sec>
<sec id="sec14-1741826710394305"><title>Conflicts of interest</title>
<p>Dr Dallongeville received institutional research grants from Astra Zeneca, Pfizer, Sanofi Aventis and participated in boards from Astra Zeneca, MSD, Sanofi Aventis.</p>
<p>Dr Bhatt received institutional research grants from Astra Zeneca, Bristol-Myers Squibb, Eisai, Ethicon, Heartscape, Sanofi Aventis, The Medicines Company.</p>
<p>Dr Steg received a research grant from Sanofi Aventis (1999–2008); is on the Speakers’ bureau for Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Menarini, Medtronic, Nycomed, Pierre Fabre, Sanofi Aventis, Servier, and The Medicines Company; is on the consulting/advisory boards for Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Endotis, GlaxoSmithKline, Medtronic, MSD, Nycomed, Sanofi Aventis, Servier, and The Medicines Company; and is a stockholder for Aterovax.</p>
<p>Dr Ravaud has received research grants from Sanofi Aventis.</p>
<p>Dr Wilson has received grant support from Sanofi Aventis.</p>
<p>Dr Eagle has received grant/research support from Bristol Myers Squibb, Blue Cross Blue Shield of Michigan, NIH, Sanofi Aventis, the Mardigian Foundation Varbedian Fund, GORE, and the Hewlett Foundation; and is a consultant for NIH NHLBI, Sanofi Aventis and the Robert Wood Johnson Foundation.</p>
<p>Dr Goto has received honoraria and consulting fees from Eisai, Sanofi Aventis, Daiichi-Sankyo, GlaxoSmithKline, Bristol-Myers Scribb, Otsuka, Bayer, Schering-Plough, Takeda, Astellas, AstraZeneca, Novartis and Kowa; research grants from Pfizer, Ono, Eisai, Otsuka, Daiichi-Sankyo, Sanofi Aventis, Takeda and Astellas within the past 3 years.</p>
<p>Dr Mas has received consulting fees from Sanofi Aventis, Servier, and Bristol-Myers Squibb; and lecture fees from Sanofi Aventis, Bristol-Myers Squibb, and Boehringer Ingelheim.</p>
<p>Dr Montalescot discloses the following relationships: Research Grants from Bristol Myers Squibb, Sanofi Aventis Group, Eli Lilly, Guerbet Medical, Medtronic, Boston Scientific, Cordis, Stago, Centocor, Fondation de France, INSERM, Fédération Française de Cardiologie, Société Française de Cardiologie; Consulting fees from Sanofi Aventis Group, Eli Lilly, Bristol-Myers Squibb, The Medicines Company, and Schering-Plough. He has also received lecture fees from Sanofi Aventis, Eli Lilly, Bristol-Myers Squibb, Merck Sharpe &amp; Dohme, Cordis, GlaxoSmithKline, and Schering-Plough.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-1741826710394305"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whitlock</surname><given-names>G</given-names></name><name><surname>Lewington</surname><given-names>S</given-names></name><name><surname>Sherliker</surname><given-names>P</given-names></name><name><surname>Clarke</surname><given-names>R</given-names></name><name><surname>Emberson</surname><given-names>J</given-names></name><name><surname>Halsey</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies</article-title>. <source>Lancet</source> <year>2009</year>; <volume>373</volume>(<issue>9669</issue>): <fpage>1083</fpage>–<lpage>1096</lpage>.</citation></ref>
<ref id="bibr2-1741826710394305"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McGee</surname><given-names>DL</given-names></name></person-group>. <article-title>Body mass index and mortality: a meta-analysis based on person-level data from twenty-six observational studies</article-title>. <source>Ann Epidemiol</source> <year>2005</year>; <volume>15</volume>(<issue>2</issue>): <fpage>87</fpage>–<lpage>97</lpage>.</citation></ref>
<ref id="bibr3-1741826710394305"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Romero-Corral</surname><given-names>A</given-names></name><name><surname>Montori</surname><given-names>VM</given-names></name><name><surname>Somers</surname><given-names>VK</given-names></name><name><surname>Korinek</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>RJ</given-names></name><name><surname>Allison</surname><given-names>TG</given-names></name><etal/></person-group>. <article-title>Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies</article-title>. <source>Lancet</source> <year>2006</year>; <volume>368</volume>(<issue>9536</issue>): <fpage>666</fpage>–<lpage>678</lpage>.</citation></ref>
<ref id="bibr4-1741826710394305"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oreopoulos</surname><given-names>A</given-names></name><name><surname>Padwal</surname><given-names>R</given-names></name><name><surname>Norris</surname><given-names>CM</given-names></name><name><surname>Mullen</surname><given-names>JC</given-names></name><name><surname>Pretorius</surname><given-names>V</given-names></name><name><surname>Kalantar-Zadeh</surname><given-names>K</given-names></name></person-group>. <article-title>Effect of obesity on short- and long-term mortality postcoronary revascularization: a meta-analysis</article-title>. <source>Obesity (Silver Spring)</source> <year>2008</year>; <volume>16</volume>(<issue>2</issue>): <fpage>442</fpage>–<lpage>450</lpage>.</citation></ref>
<ref id="bibr5-1741826710394305"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oreopoulos</surname><given-names>A</given-names></name><name><surname>Padwal</surname><given-names>R</given-names></name><name><surname>Kalantar-Zadeh</surname><given-names>K</given-names></name><name><surname>Fonarow</surname><given-names>GC</given-names></name><name><surname>Norris</surname><given-names>CM</given-names></name><name><surname>McAlister</surname><given-names>FA</given-names></name></person-group>. <article-title>Body mass index and mortality in heart failure: a meta-analysis</article-title>. <source>Am Heart J</source> <year>2008</year>; <volume>156</volume>(<issue>1</issue>): <fpage>13</fpage>–<lpage>22</lpage>.</citation></ref>
<ref id="bibr6-1741826710394305"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lavie</surname><given-names>CJ</given-names></name><name><surname>Osman</surname><given-names>AF</given-names></name><name><surname>Milani</surname><given-names>RV</given-names></name><name><surname>Mehra</surname><given-names>MR</given-names></name></person-group>. <article-title>Body composition and prognosis in chronic systolic heart failure: the obesity paradox</article-title>. <source>Am J Cardiol</source> <year>2003</year>; <volume>91</volume>(<issue>7</issue>): <fpage>891</fpage>–<lpage>894</lpage>.</citation></ref>
<ref id="bibr7-1741826710394305"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lavie</surname><given-names>CJ</given-names></name><name><surname>Mehra</surname><given-names>MR</given-names></name><name><surname>Milani</surname><given-names>RV</given-names></name></person-group>. <article-title>Obesity and heart failure prognosis: paradox or reverse epidemiology?</article-title>. <source>Eur Heart J</source> <year>2005</year>; <volume>26</volume>(<issue>1</issue>): <fpage>5</fpage>–<lpage>7</lpage>.</citation></ref>
<ref id="bibr8-1741826710394305"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>FB</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Solomon</surname><given-names>CG</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Speizer</surname><given-names>FE</given-names></name><etal/></person-group>. <article-title>The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up</article-title>. <source>Arch Intern Med</source> <year>2001</year>; <volume>161</volume>(<issue>14</issue>): <fpage>1717</fpage>–<lpage>1723</lpage>.</citation></ref>
<ref id="bibr9-1741826710394305"><label>9</label><citation citation-type="journal"><collab>National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)</collab>. <article-title>Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report</article-title>. <source>Circulation</source> <year>2002</year>; <volume>106</volume>(<issue>25</issue>): <fpage>3143</fpage>–<lpage>31421</lpage>.</citation></ref>
<ref id="bibr10-1741826710394305"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haffner</surname><given-names>SM</given-names></name><name><surname>Lehto</surname><given-names>S</given-names></name><name><surname>Ronnemaa</surname><given-names>T</given-names></name><name><surname>Pyorala</surname><given-names>K</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name></person-group>. <article-title>Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction</article-title>. <source>N Engl J Med</source> <year>1998</year>; <volume>339</volume>(<issue>4</issue>): <fpage>229</fpage>–<lpage>234</lpage>.</citation></ref>
<ref id="bibr11-1741826710394305"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miettinen</surname><given-names>H</given-names></name><name><surname>Lehto</surname><given-names>S</given-names></name><name><surname>Salomaa</surname><given-names>V</given-names></name><name><surname>Mahonen</surname><given-names>M</given-names></name><name><surname>Niemela</surname><given-names>M</given-names></name><name><surname>Haffner</surname><given-names>SM</given-names></name><etal/></person-group>. <article-title>Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group</article-title>. <source>Diabetes Care</source> <year>1998</year>; <volume>21</volume>(<issue>1</issue>): <fpage>69</fpage>–<lpage>75</lpage>.</citation></ref>
<ref id="bibr12-1741826710394305"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Natarajan</surname><given-names>S</given-names></name><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>G</given-names></name><name><surname>Lipsitz</surname><given-names>SR</given-names></name><name><surname>McGee</surname><given-names>DL</given-names></name></person-group>. <article-title>Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease</article-title>. <source>Arch Intern Med</source> <year>2003</year>; <volume>163</volume>(<issue>14</issue>): <fpage>1735</fpage>–<lpage>1740</lpage>.</citation></ref>
<ref id="bibr13-1741826710394305"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vaccaro</surname><given-names>O</given-names></name><name><surname>Eberly</surname><given-names>LE</given-names></name><name><surname>Neaton</surname><given-names>JD</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Riccardi</surname><given-names>G</given-names></name><name><surname>Stamler</surname><given-names>J</given-names></name></person-group>. <article-title>Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial</article-title>. <source>Arch Intern Med</source> <year>2004</year>; <volume>164</volume>(<issue>13</issue>): <fpage>1438</fpage>–<lpage>1443</lpage>.</citation></ref>
<ref id="bibr14-1741826710394305"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CD</given-names></name><name><surname>Folsom</surname><given-names>AR</given-names></name><name><surname>Pankow</surname><given-names>JS</given-names></name><name><surname>Brancati</surname><given-names>FL</given-names></name></person-group>. <article-title>Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction</article-title>. <source>Circulation</source> <year>2004</year>; <volume>109</volume>(<issue>7</issue>): <fpage>855</fpage>–<lpage>860</lpage>.</citation></ref>
<ref id="bibr15-1741826710394305"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krempf</surname><given-names>M</given-names></name><name><surname>Parhofer</surname><given-names>KG</given-names></name><name><surname>Steg</surname><given-names>PG</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Ohman</surname><given-names>EM</given-names></name><name><surname>Rother</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)</article-title>. <source>Am J Cardiol</source> <year>2010</year>; <volume>105</volume>(<issue>5</issue>): <fpage>667</fpage>–<lpage>671</lpage>.</citation></ref>
<ref id="bibr16-1741826710394305"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nicholls</surname><given-names>SJ</given-names></name><name><surname>Tuzcu</surname><given-names>EM</given-names></name><name><surname>Kalidindi</surname><given-names>S</given-names></name><name><surname>Wolski</surname><given-names>K</given-names></name><name><surname>Moon</surname><given-names>KW</given-names></name><name><surname>Sipahi</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials</article-title>. <source>J Am Coll Cardiol</source> <year>2008</year>; <volume>52</volume>(<issue>4</issue>): <fpage>255</fpage>–<lpage>262</lpage>.</citation></ref>
<ref id="bibr17-1741826710394305"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Flaherty</surname><given-names>JD</given-names></name><name><surname>Davidson</surname><given-names>CJ</given-names></name></person-group>. <article-title>Diabetes and coronary revascularization</article-title>. <source>JAMA</source> <year>2005</year>; <volume>293</volume>(<issue>12</issue>): <fpage>1501</fpage>–<lpage>1508</lpage>.</citation></ref>
<ref id="bibr18-1741826710394305"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Bacquer</surname><given-names>D</given-names></name><name><surname>Dallongeville</surname><given-names>J</given-names></name><name><surname>Heidrich</surname><given-names>J</given-names></name><name><surname>Kotseva</surname><given-names>K</given-names></name><name><surname>Reiner</surname><given-names>Z</given-names></name><name><surname>Gaita</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Management of overweight and obese patients with coronary heart disease across Europe</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2010</year>; <volume>17</volume>(<issue>4</issue>): <fpage>447</fpage>–<lpage>454</lpage>.</citation></ref>
<ref id="bibr19-1741826710394305"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohman</surname><given-names>EM</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Steg</surname><given-names>PG</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name><name><surname>Hirsch</surname><given-names>AT</given-names></name><name><surname>Liau</surname><given-names>CS</given-names></name><etal/></person-group>. <article-title>The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design</article-title>. <source>Am Heart J</source> <year>2006</year>; <volume>151</volume>(<issue>4</issue>): <fpage>786</fpage>–<lpage>10</lpage>.</citation></ref>
<ref id="bibr20-1741826710394305"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Steg</surname><given-names>PG</given-names></name><name><surname>Ohman</surname><given-names>EM</given-names></name><name><surname>Hirsch</surname><given-names>AT</given-names></name><name><surname>Ikeda</surname><given-names>Y</given-names></name><name><surname>Mas</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis</article-title>. <source>JAMA</source> <year>2006</year>; <volume>295</volume>(<issue>2</issue>): <fpage>180</fpage>–<lpage>189</lpage>.</citation></ref>
<ref id="bibr21-1741826710394305"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steg</surname><given-names>PG</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Wilson</surname><given-names>PW</given-names></name><name><surname>D’Agostino</surname><given-names>R</given-names><suffix>Sr</suffix></name><name><surname>Ohman</surname><given-names>EM</given-names></name><name><surname>Rother</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>One-year cardiovascular event rates in outpatients with atherothrombosis</article-title>. <source>JAMA</source> <year>2007</year>; <volume>297</volume>(<issue>11</issue>): <fpage>1197</fpage>–<lpage>1206</lpage>.</citation></ref>
<ref id="bibr22-1741826710394305"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>LM</given-names></name><name><surname>Dickstein</surname><given-names>K</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Kristianson</surname><given-names>K</given-names></name><name><surname>Willenheimer</surname><given-names>R</given-names></name></person-group>. <article-title>The prognostic importance of body mass index after complicated myocardial infarction</article-title>. <source>J Am Coll Cardiol</source> <year>2005</year>; <volume>45</volume>(<issue>1</issue>): <fpage>156</fpage>–<lpage>158</lpage>.</citation></ref>
<ref id="bibr23-1741826710394305"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mak</surname><given-names>KH</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Shao</surname><given-names>M</given-names></name><name><surname>Haffner</surname><given-names>SM</given-names></name><name><surname>Hamm</surname><given-names>CW</given-names></name><name><surname>Hankey</surname><given-names>GJ</given-names></name><etal/></person-group>. <article-title>The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease</article-title>. <source>Eur Heart J</source> <year>2009</year>; <volume>30</volume>(<issue>7</issue>): <fpage>857</fpage>–<lpage>865</lpage>.</citation></ref>
<ref id="bibr24-1741826710394305"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abdulla</surname><given-names>J</given-names></name><name><surname>Kober</surname><given-names>L</given-names></name><name><surname>Abildstrom</surname><given-names>SZ</given-names></name><name><surname>Christensen</surname><given-names>E</given-names></name><name><surname>James</surname><given-names>WP</given-names></name><name><surname>Torp-Pedersen</surname><given-names>C</given-names></name></person-group>. <article-title>Impact of obesity as a mortality predictor in high-risk patients with myocardial infarction or chronic heart failure: a pooled analysis of five registries</article-title>. <source>Eur Heart J</source> <year>2008</year>; <volume>29</volume>(<issue>5</issue>): <fpage>594</fpage>–<lpage>601</lpage>.</citation></ref>
<ref id="bibr25-1741826710394305"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uretsky</surname><given-names>S</given-names></name><name><surname>Messerli</surname><given-names>FH</given-names></name><name><surname>Bangalore</surname><given-names>S</given-names></name><name><surname>Champion</surname><given-names>A</given-names></name><name><surname>Cooper-Dehoff</surname><given-names>RM</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Obesity paradox in patients with hypertension and coronary artery disease</article-title>. <source>Am J Med</source> <year>2007</year>; <volume>120</volume>(<issue>10</issue>): <fpage>863</fpage>–<lpage>870</lpage>.</citation></ref>
<ref id="bibr26-1741826710394305"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gruson</surname><given-names>E</given-names></name><name><surname>Montaye</surname><given-names>M</given-names></name><name><surname>Kee</surname><given-names>F</given-names></name><name><surname>Wagner</surname><given-names>A</given-names></name><name><surname>Bingham</surname><given-names>A</given-names></name><name><surname>Ruidavets</surname><given-names>JB</given-names></name><etal/></person-group>. <article-title>Anthropometric assessment of abdominal obesity and coronary heart disease risk in men: the PRIME study</article-title>. <source>Heart</source> <year>2010</year>; <volume>96</volume>(<issue>2</issue>): <fpage>136</fpage>–<lpage>140</lpage>.</citation></ref>
<ref id="bibr27-1741826710394305"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zeller</surname><given-names>M</given-names></name><name><surname>Steg</surname><given-names>PG</given-names></name><name><surname>Ravisy</surname><given-names>J</given-names></name><name><surname>Lorgis</surname><given-names>L</given-names></name><name><surname>Laurent</surname><given-names>Y</given-names></name><name><surname>Sicard</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Relation between body mass index, waist circumference, and death after acute myocardial infarction</article-title>. <source>Circulation</source> <year>2008</year>; <volume>118</volume>(<issue>5</issue>): <fpage>482</fpage>–<lpage>490</lpage>.</citation></ref>
<ref id="bibr28-1741826710394305"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Canoy</surname><given-names>D</given-names></name><name><surname>Boekholdt</surname><given-names>SM</given-names></name><name><surname>Wareham</surname><given-names>N</given-names></name><name><surname>Luben</surname><given-names>R</given-names></name><name><surname>Welch</surname><given-names>A</given-names></name><name><surname>Bingham</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Body fat distribution and risk of coronary heart disease in men and women in the European Prospective Investigation Into Cancer and Nutrition in Norfolk cohort: a population-based prospective study</article-title>. <source>Circulation</source> <year>2007</year>; <volume>116</volume>(<issue>25</issue>): <fpage>2933</fpage>–<lpage>2943</lpage>.</citation></ref>
<ref id="bibr29-1741826710394305"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kragelund</surname><given-names>C</given-names></name><name><surname>Hassager</surname><given-names>C</given-names></name><name><surname>Hildebrandt</surname><given-names>P</given-names></name><name><surname>Torp-Pedersen</surname><given-names>C</given-names></name><name><surname>Kober</surname><given-names>L</given-names></name></person-group>. <article-title>Impact of obesity on long-term prognosis following acute myocardial infarction</article-title>. <source>Int J Cardiol</source> <year>2005</year>; <volume>98</volume>(<issue>1</issue>): <fpage>123</fpage>–<lpage>131</lpage>.</citation></ref>
<ref id="bibr30-1741826710394305"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dagenais</surname><given-names>GR</given-names></name><name><surname>Yi</surname><given-names>Q</given-names></name><name><surname>Mann</surname><given-names>JF</given-names></name><name><surname>Bosch</surname><given-names>J</given-names></name><name><surname>Pogue</surname><given-names>J</given-names></name><name><surname>Yusuf</surname><given-names>S</given-names></name></person-group>. <article-title>Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease</article-title>. <source>Am Heart J</source> <year>2005</year>; <volume>149</volume>(<issue>1</issue>): <fpage>54</fpage>–<lpage>60</lpage>.</citation></ref>
</ref-list>
</back>
</article>